Hyewon Lee

Hyewon Lee

Auto-generated profile, based on publicly available information

Hyewon Lee

National Cancer Center, Goyang, Korea, Republic Of

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
HSHyoeun Shim
Hyoeun Shim
JHJoo Hee Ha
Joo Hee Ha
HLHyewon Lee
Hyewon Lee
JSJi Yeon Sohn
Ji Yeon Sohn
HKHyun Ju Kim
Hyun Ju Kim
SKSun-Young Kong
Sun-Young Kong
We evaluated the association between the expression of myeloid antigens on neoplastic plasma cells and patient prognosis. The expression status of CD13, CD19, CD20, CD33, CD38, CD56, and CD117 was analyzed on myeloma cells from 55 newly diagnosed patients, including 36 men (65%), of median age 61 years (range: 38–78). Analyzed clinical characteristics and laboratory parameters were as follows: serumβ2-microglobulin, lactate dehydrogenase, calcium, albumin, hemoglobin, serum creatinine concentrations, bone marrow histology, and cytogenetic findings. CD13+ and CD33+ were detected in 53% and 18%, respectively. Serum calcium (P=0.049) and LDH (P=0.018) concentrations were significantly higher and morphologic subtype of immature or plasmablastic was more frequent in CD33+ than in CD33− patients (P=0.022). CD33 and CD13 expression demonstrate a potential prognostic impact and were associated with lower overall survival (OS;P=0.001andP=0.025) in Kaplan-Meier analysis. Multivariate analysis showed that CD33 was independently prognostic of shorter progression free survival (PFS;P=0.037) and OS (P=0.001) with correction of clinical prognostic factors. This study showed that CD13 and CD33 expression associated with poor prognosis in patients with MM implicating the need of analysis of these markers in MM diagnosis.

1 January 2017 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
SPSun Seob Park
Sun Seob Park
HLHyewon Lee
Hyewon Lee
WPWeon Seo Park
Weon Seo Park
SHSang Hyun Hwang
Sang Hyun Hwang
SCSang Il Choi
Sang Il Choi
HEHyeon-Seok Eom
Hyeon-Seok Eom
Park SS, et al. Infect Chemother. 2017 Jun;49(2):142-145. https://doi.org/10.3947/ic.2017.49.2.142

1 January 2021 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JJJongheon Jung
Jongheon Jung
HLHyewon Lee
Hyewon Lee
YSYang-Gun Suh
Yang-Gun Suh
HEHyeon-Seok Eom
Hyeon-Seok Eom
ELEunyoung Lee
Eunyoung Lee
Jung J, et al. J Korean Med Sci. 2021 Jan;36(8):e55. https://doi.org/10.3346/jkms.2021.36.e55

4 June 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
HLHo Sup Lee
Ho Sup Lee
KKKihyun Kim
Kihyun Kim
DYDok Hyun Yoon
Dok Hyun Yoon
JKJIN SEOK KIM
JIN SEOK KIM
SBSoo-Mee Bang
Soo-Mee Bang
CMChang-Ki Min
Chang-Ki Min
Waldenström’s macroglobulinemia (WM) is a B-cell proliferative malignancy characterized by immunoglobulin M monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic cells. Clinical features and cytogenetics of WM in Asia including Republic of Korea remain unclear. Moreover, no study has reported treatment outcomes in patients with WM treated with novel agent combined with conventional chemotherapy. This study investigated clinical features and assessed treatment outcomes with novel agent and conventional chemotherapy in Republic of Korea. Data from all (n=71) patients with newly diagnosed WM at 17 hospitals who received chemotherapy between January 2005 and December 2012 were collected retrospectively. The median age of patients was 66 years (range: 37–92 years) and male to female ratio was 5 : 1. Patients treated with novel agent combined chemotherapy displayed higher overall response rate (ORR) compared to conventional chemotherapy alone (92.9% versus 52.6%,P=0.006). The 5-year overall survival rate was 62.6% (95% confidence interval: 34.73–111.07). Use of novel agents produced higher ORR but survival benefit was not apparent due to the small number of patients and short follow-up duration. Further studies are needed to confirm the efficacy of novel agents in patients with WM.

22 October 2026 in Blood
Verified
Journal Article
Open access
WKWon Seog Kim
Won Seog Kim
SKSeok Jin Kim
Seok Jin Kim
DYDok Hyun Yoon
Dok Hyun Yoon
HCHyungwoo Cho
Hyungwoo Cho
SYSang Eun Yoon
Sang Eun Yoon
SCSu-Hee Cho
Su-Hee Cho
Anbalcabtagene autoleucel (anbal-cel) is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy incorporating dual PD-1 and TIGIT knockdown to enhance antitumor function and durability. We report results from a phase 1 and 2 study in patients with relapsed or refractory large B-cell lymphoma. In phase 2, 79 patients received anbal-cel, and its efficacy was evaluated in 73 patients. The complete response (CR) and partial response rates were 67.1% and 8.2%, respectively. Median progression-free survival (PFS) was 6.04 months (95% confidence interval, 4.34-16.46), and the 6-, 12-, and 18-month PFS rates were 50.9%, 41.1%, and 35.2%, respectively. Median overall survival (OS) was not reached, with 12- and 18-month OS rates of 66.6% and 57.3%, respectively. CAR T-cell expansion (Cmax) was significantly greater in responders than in nonresponders (median Cmax, 20 403 vs 8580 copies per μg). Patients were categorized into long-term response (LR) group or non-LR group based on sustained CR at 6 months. Reduced PD-1 and TIGIT expression on CAR+ T cells was observed in the LR group. Most patients (97.5%) experienced grade ≥3 adverse events, most commonly neutropenia (93.7%), followed by thrombocytopenia (41.8%) and anemia (30.4%). Cytokine release syndrome (CRS) and neurological events occurred in 57.0% and 13.9% of patients, respectively. Grade 3 CRS occurred in 8.9% of patients, with no grade 4 events reported, and grade ≥3 neurological events occurred in 3.8% of patients. Serious infections occurred in 25.3% of patients, including grade 5 infection reported in 3 patients. This trial was registered at www.clinicaltrials.gov as #NCT04836507.

1 July 2020 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
YCYousun Chung
Yousun Chung
SSSeungwon Shin
Seungwon Shin
HSHyoeun Shim
Hyoeun Shim
JSJi Yeon Sohn
Ji Yeon Sohn
LDLee Dong-eun
Lee Dong-eun
M.M.S.
M.S.
Yousun Chung, M.D., Seungwon Shin, Ph.D., Hyoeun Shim, MD, Ph.D., Ji Yeon Sohn, M.D., Dong-eun Lee, M.S., Hyewon Lee, M.D., Ph.D., Hyeon-Seok Eom, M.D., Ph.D., Kwang Gi Kim, Ph.D., and Sun-Young Kong, M.D., Ph.D.. Ann Lab Med 2020;40:312-6. https://doi.org/10.3343/alm.2020.40.4.312